infected host. 4 As protective immunity is T-cell-mediated and the antigen of Leishmania is among those presumed in the context to the MHC molecule, a greater understanding of the parasite antigen that triggers the disparate Th subset expansion can aid in the development of a vaccine strategy against the disease.
Various strategies have been employed to date to develop specific antileishmanial vaccines such as killed parasites, 5 live attenuated parasites, 6 subunit vaccines using proteins of different stages of the parasite life cycle and DNA vaccines, 7-10 dendritic cell-based vaccines 11 and salivary antigen-based vaccines. 12, 13 Many of these strategies have resulted in protection of the mouse model. However, with the exception of Leish-F1 (a recombinant fusion protein of LmsTI-1, TSA and LeIF), none have entered human trial.
14 Murine studies emphasize the importance of the CD4 + T cell in activating a parasitespecific Th1 response for protection against leishmaniasis (mediated via IL-12, IFN-γ) and the tumour necrosis factor, which induces ROS and RNS generation in macrophages leading to disease clearance.
These mechanisms, however, remain suppressed during the severe stages of the infection, in which case IL-10 secretion by CD4 + T cells contribute to disease progression. 15, 16 As previously shown, CD4 In VL and experimental studies, CD8 + T cells have been shown to be protective. In CL, however, studies show the opposite: that CD8 + T cells are pathogenic because of the powerful cytotoxic activities they exert. 18 In most recombinant proteins, polyproteins and DNA vaccines, protection was associated with the induction of antigen-specific IFN-γ-producing CD8 + T cells. Previous studies explored that the antigens-tested KMP11, 19 GP63, 20 P8 and gp46, 21 HASPB1, 7 CPB, 22 nucleosomal histones, 23 LmsTI1 and TSA 24 are processed through the initiation of the CD8 + T-cell pathway in the Leishmania species that also emphasizes the critical role played by class I MHC molecule.
Recently, both the protective and therapeutic peptide-based vaccine concepts have drawn considerable focus in the field of Leishmania. As the evidence continues to build about the role of CD8 + T cells via HLA-A*0201, the restricted peptide in the protection might open up a new way in the battle against visceral leishmaniasis.
25,26
Lysosomal cysteine proteases (CP) of Leishmania, including cysteine proteases type I (CPB), II (CPA) and III (CPC), are conserved and functionally important proteolytic enzymes regulating cell cycle and host-parasite interactions that have been found to be immunogenic in mice. 27 Amongst the cysteine proteases, the efficiency of type III (CPC) CP demonstrated stronger antigenicity than type I and II.
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Efforts were made in this study to identify potential immunogenic MHC class I-specific T-cell epitopes from LdCPC. Cross-HLA-binding affinity was predicted. Immunogenicity of the synthetic peptides (alone or as in cocktail) in terms of T-cell activation was validated in treated VL subjects by analysing peptide-specific cytokine production by CD8 + T cells.
| METHODOLOGY

| Peptide curation and analysis
The amino acid sequence of LdCPC (AFV46426) was downloaded from the National Center for Biotechnology Information (NCBI) protein database (http://www.ncbi.nlm.nih.gov/protein). Emphasis was placed on 9-mer long peptides as they bind more frequently with HLA class I allele. The HLA A0201 restricted epitopes were predicted according to our previously described methodology. 28 org/mhci/). Peptides with 100% query coverage and 100% identity to human proteins were excluded from the study. The epitopes selected by ultimate consensus (a promising binding score predicted by at least three programmes) were kept for further analysis.
| Structure prediction of peptides and their binding analysis with the HLA A0201 allele
The initial structure of the peptides was built using a tLeap module of amber. A short minimization was applied using an Amber99SB force field for clearing all steric clashes in the linear starting structure. The coordinates of these peptides were then processed in the Desmond MD system for further structure prediction. A simulated annealing (SA) protocol was applied (at various temperature scales) in an explicit solvent condition over peptides to obtain structural ensembles, and the frames were saved at intervals of 4.8 ps for analysis. The clustering of conformers was performed for each peptide (Schrödinger, LLC) based on the atom-positional root-mean-square difference (RMSD).
The crystal structure of HLA A*0201 (PDB ID: 1I4F) was downloaded from the PDB databank. 10-mer peptide was removed and processed in the Protein Preparation Wizard (Schrödinger, LLC) to rectify any problem in the bond order or regarding overlapping atoms and missing atoms. This decamer antigenic peptide was used as a positive control for docking studies whereas a mouse H-2Kb-restricted peptide, VSV8 (RGYVYQGL), was used as the negative control.
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Docking was
performed between the crystal structure of the HLA A*0201 and the peptides using the ZDOCK server (zdock.umassmed.edu) with predefined parameters. The ZDOCK server provides a rapid and effective means to generate models of protein-protein complexes and
KEY FINDINGS
• Immunoinformatics analysis of LdCPC revealed 3 HLA A0201 restricted epitopes.
• Two peptides (LLATTVSGL (P1) and LMTNGPLEV (P3)) stabilized HLA-A*02.
• Stimulation of PBMCs with epitopes upregulated the IFN-γ production.
symmetric multimers via a user-friendly web interface. 35 MD simulation was carried out according to our previously described methodology. 36 The simulation was continued for a time scale of 5 ns. To predict the antigenicity nature of the predicted peptide, the Kolaskar 
| Peptide synthesis
Peptides were synthesized with more than 95% purity by BioSynthesis Inc. (Peptide 2.0, Chantilly, VA, USA). Lyophilized powder was dissolved in 10% dimethyl sulphoxide or DMSO (Sigma, Steinheim, Germany) and stored at −80°C until use.
| Study subjects
Twenty-nine VL recovered individuals, 24 healthy donors and three ac- 
| Peptide-binding assay
The ability of the synthetic peptides to stabilize the HLA-A*02 mole- 
| T-cell proliferation assay
The T-cell proliferation assay was performed according to the protocol described earlier with certain modifications. 41 Peripheral blood mononuclear cells from three treated VL subjects were isolated and stained
ester, Biolegend) and seeded in RPMI-1640 complete medium. The cells were incubated at 37°C in 5% CO 2 for 5 days in the presence or absence of an antigen or selected peptides (20 μg/mL). H-2Kb binding vesicular stomatitis virus nucleocapsid protein-derived peptide (RGYVYQGL) or VSV8 was used as negative control as described previously, 34 and SLA was used as positive control. On day 5, the cells were washed and stained with anti-CD3-PerCP and anti-CD8-PE (BD Biosciences) and tested for fluorescence using a Becton Dickinson
FACSCalibur. The cells were also analysed with CellQuest software.
| Cytokine enzyme-linked immunosorbent assay (ELISA) for total IFN-γ release
Peripheral blood mononuclear cells (1×10 6 /mL) from five VL treated subjects and six healthy control subjects were suspended in 2 mL RPMI 1640 (Sigma) supplemented with 10% human FBS (Sigma), 1% HEPES (Sigma), 2 mmol/L L.Glutamine (Sigma) and 0.1% Gentamicin (Sigma). They were dispensed in 24-well culture plates (Nunc, Roskilde, USA) and incubated overnight at 37°C and 5% CO 2 . After 24 hours, the cells were stimulated with two different peptide cocktails at 5 μg/mL/peptide (cocktail-5) and 10 μg/mL/peptide (cocktail-10).
Control panels with an unstimulated (UNS) culture, SLA or PHA were run parallel to all experiments. In this study, PHA and SLA were used as nonspecific and specific antigen positive control, respectively. The quantitative yield of IFN-γ was determined by enzyme-linked immunosorbent assay (ELISA; BD Biosciences, USA) after 5 days of incubation using a supernatant.
| Intracellular cytokine produced from CD8 + T cells against selected peptide in fresh VL as well as in treated VL subjects
To detect the intracellular cytokine produced from the CD8 + T cell in VL treated subjects, peripheral blood mononuclear cells (PBMCs) from five VL treated and four healthy subjects (HLA-A2) were isolated. The PBMCs (1×10 6 /mL) were cultured in 6-well plates for overnight incubation at 5% CO 2 with one of the individual peptides (P1 and P3). Stimulation with SLA was run in parallel to all experiments as described previously. 10 After over- 
| Statistical analysis
All data were expressed as mean±SE (standard error of the mean).
Significance was accessed by a student t test and a value of P<.05 was considered to be significant. Statistical analysis was carried out using
GraphPad Prism 5 software.
| RESULTS
| Identification of potential HLA A0201 restricted epitopes
The retrieved amino acid sequence of LdCPC was scanned for the detection of potential T-cell epitopes (HLA A*0201) using five different online algorithms. The most important criteria were based on absolute scores from five mostly used online algorithms: SYFPEITHI with the score of more than 20, RANKPEP binding threshold set at 2%, EpiJen output cut-off set at 5%, a nHLAPred score more than 0.5 and an IEDB score less than 5 (percentile rank). Only those peptides commonly predicted by at least of the three algorithms were considered. Based on the ranking scores, three peptides were selected for further study ( Table 1 ). The threshold value for each server was adopted from the published literature. T A B L E 1 Characteristics of in silico predicted Leishmania donovani CPC-specific CD8 + T cell 9-mer peptides restricted to HLA-A*0201 allele the threshold level (1.000) and were highly antigenic (Fig. S1 ). The results obtained from the NetMHCpan 2.8 web server revealed that P1, P2 and P3 can be presented by 9 HLA-A2 alleles each, respectively (Table 2) .
| Determine the binding affinity of peptides to HLA-A*02 molecules
The binding affinity of the selected peptides with HLA-A*02 molecules was determined by the T2 cell line binding assay. As described in Figure 2 , peptides P1 and P3 revealed the strongest binding affinity with FI value 2.26 and 1.29, respectively, whereas P2 showed an intermediate/weak binding affinity (FI value −0.47). The FI value peptides, P1 and P3, were above the threshold value and were selected for immunogenicity studies in HLA-A*02 positive VL treated subjects.
| HLA-A*02 typing
Using FACS analysis, we were able to screen 9, 9 and 2 HLA-A2 positive individuals out of 29 VL recovered patients (34.1%), 24
healthy donors (37.5%) and three active VL patients (66.6%), respectively. Figure S2 shows the representative plot for HLA A02
positive and negative samples. Here, the T2 cell line was used as positive control.
| Cellular proliferation
To assess the influence of MHC class I restricted epitopes on T-cell proliferation further, CFSE proliferation assays were performed in three VL treated subjects. The peptides P1 and P3 were found to stimulate the CD3 +ve CD8 +ve T lymphocytes proliferation significantly as compared to unstimulated and negative control (P<.05, Figure 3 ).
At least three generations were observed against P1 and P3. Costimulation with the VSV8 peptide (negative control) also did not proliferate the cell efficiently (Figure 3 ).
| Cytokine response (IFN-γ and IL-10) against the peptide in VL treated subjects
We measured the secreted levels of IFN-γ to assess the overall abili- Similarly, results were also obtained from FACS analysis (expressed in % gated cell). They indicated that the pretreatment of PBMC S with these peptides, P1 and P3, significantly triggered CD3 +ve CD8 +ve cells for intracellular IFN-γ production. Significantly, upregulated CD3 +ve CD8 +ve IFN-γ was observed in treated VL subjects against P1
and P3 peptides as compared to the unstimulated culture condition as well as healthy control. No such differences in IFN-γ production were observed in the treated VL unstimulated culture condition as compared to the healthy unstimulated culture condition ( Figure 5 ).
In contrast, low levels of IL-10 were detected in vitro with each The cross presentation ability was predicted by NetMHCpan 2.8 web server. The relative predicted binding affinity of the peptide with other HLA allele was less than 500 nmol/L.
T A B L E 2
The cross presentation ability of the predicted CTL epitopes by diverse HLA-A2 allele 
| DISCUSSION
As previously reported, nearly 80% of the Leishmania-infected population develop protective immunity and clear their infection naturally. 42 More than 85% of the cured VL subjects showed some degree of protection against L. donovani reinfection. 43, 44 Today, immunoinformatic tools are frequently in access for epitope mapping. Although, these tools have been used to identify specific epitopes, there is no consensus on most of the algorithms. In this study, using five different kinds of software, potential CD8 + T-cell epitopes were predicted based on the theory of Trost et al. 45 by combining the predictions from five different tools. RANKPEP predicts peptide binders to MHC-I molecules from protein sequences or sequence alignments using position specific scoring matrices (PSSMs). In addition, it predicts those MHC-I ligands whose C-terminal end is likely to be the result of proteasomal cleavage, which enhances the prediction accuracy. Various groups have established the utility of the matrix-based algorithms such as BIMAS and SYFPEITHI in predicting antigen-specific CTL epitopes. [46] [47] [48] [49] In agreement with the theory of Trost et al., all the predicted epitopes derived from Leishmania donovani 3-ectonucleotidase showed either high or moderate binding affinity with HLA-A*02 molecules and elicited the CD8 + T-cell response in Leishmania-sensitized subjects. 50 Similarly, the cocktail of peptides derived from Leishmania triggered CD8 + IFN-γ against treated VL subjects as well as in the vaccinated mice model.
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Therefore, we have predicted the HLA-A*0201-restricted CD8 + Tcell epitope with five most-commonly used algorithms: SYFPEITHI and BIMAS, RANKPEP, IEDB and Propred1. As previously described, Among the 10% of the consensus top scored peptides (predicted by SYFPEITHI and BIMAS), nearly 85% of the peptides can induce an immune response. 52 Therefore, it can be reasonably speculated about F I G U R E 3 Ability of P1, P3 and cocktail of peptide to proliferate T cell in vitro against PBMCs isolated from 3 HLA-A2 restricted treated VL subjects. The figure depicts CD3+ T cells that have divided 5-6 times based on CFSE dilution peaks.
Here, SLA was used as positive control which shows 5-6 T cell population whereas, against VSV8 peptide (negative control) and in unstimulated culture condition, no such proliferation was observed
The inflammatory activity of the peptide and cocktail of peptide was measured against five VL treated subjects and six healthy controls. The data suggest that cocktail-10 to be more effective than cocktail-5 in HLA A0201 positive treated subjects (peptide cocktail at 5 μg/mL/peptide (cocktail-5) and of 10 μg/mL/peptide (cocktail-10)). The peptide P1 and P3 produced more total IFN-γ in HLA A0201 positive as compared to healthy control the effectiveness of the predicted peptide to trigger the host immune cells.
The analysis of the LdCPC proteome yielded a total number of three consensus peptides, which were predicted by at least three prediction programmes and therefore believed to be energetically best fitted to the HLA peptide-binding groove ( Table 1) . As a general consensus, epitopes mimicking native human peptides will be tolerated and those peptides that do not resemble human peptides can induce an immunogenic response. We checked whether the peptides derived from LdCPC share any such identity to the human proteome by analysing the human nonredundant protein database. Our result revealed that all three peptides share a low level of sequence similarity with Homo sapiens, which defines their degree of foreignness and guarantees high specificity with low cross-reactivity. The low sequence identities will greatly reduce the likelihood of triggering an autoimmune response in human subjects. 53 Finally, Kolaskar and Tongaonkar's antigenicity method revealed that all of the peptides are highly antigenic, as most of the residues in the peptides were found above the threshold level (1.000). These data suggest that the host immune system will preferentially respond to these antigenic peptides (Fig. S1) . and P3 seem to provide a much stronger contact with the protein (Figure 7 ) as compared to P2, whereas, in the control, the same contact was being stabilized by 8-9 strong H-bonds. The results obtained from this study revealed that the average number of hydrogen bonds for P1 and P3 complexes was found to be 5, which under underwent significant change up to 3.5 nanoseconds but reached stability during the later stages of MD simulations. Although some crucial H-bonds noticed during docking were found to be broken during MD simulation, they were well compensated later by van der Waals interactions and hydrophobic contacts. This gives the assumption that, despite the dynamicity of active site residues, the ligand molecules (P1 and P3)
were still intact within the active sites.
All of the methods used in this study to predict HLA-binding epitopes are indirect methods although not all HLA binders are T-cell epitopes. 55 Even with its high sensitivity and specificity, computational analysis is just a prediction. This necessitates in vitro evaluations to confirm the ability of the predicted epitopes to elicit the immune response. Synthetic peptides were purchased, and in vitro evaluations were carried out to evaluate their efficiency. All the epitopes were produced by cells confirmed that individuals who had recovered from VL developed a specific response against P1 and P3 peptides during the active phase of their disease. In the unstimulated culture condition, no significant changes were observed in treated VL subjects as compared to the healthy control subjects. In contrary, in stimulation with either P1 or P3 against a treated VL subject, a significantly enhanced-CD3 + CD8 + T IFN-γ was observed as compared to a healthy control subject ( Figure 6 ). Here, both the peptides showed CD3 +ve CD8 +ve T cells as a major source of IFN-γ production, implying its important role in protective immunity. In contrast, no specific role of these epitopes was observed in the production of intracellular IL-10 in active as well as treated VL subjects ( Figure 6A,B) . Therefore, in the light of the effects observed for these peptides individually on the CD8 + T-cell activation on patients who had already cleared the Leishmania infection and the significance earlier shown for CD8 + T cells and also in the present study, one can speculate the protective role of the MHC class I-specific peptides of LdCPC during cure from visceral leishmaniasis.
As known, HLA alleles are highly polymorphic and the vaccine composition of epitopes must cover the population HLA diversity. The information regarding the binding ability with diverse HLA alleles will be helpful for reducing the number of epitopes, as many HLA alleles have common binding specificities although they are different in sequence.
Our data revealed that P1 and P3 can be recognized by 9 HLA-A2 alleles, respectively (Table 2 ). These three peptides were also found to be highly conserved in different Leishmania species (Leishmania don-
ovani, Leishmania major, Leishmania infantum and Leishmania chagasi).
Epitope conservancy analysis suggested that P1 is 100% conserved in all the Leishmania species whereas P3 was found to be conserved in all species except L. major. These results suggest that these peptides not only can be recognized by a larger population, but also have the ability to induce immunogenic response against diverse Leishmania species (Figure 8) . In future studies, it would be useful to challenge immunized HLA A0201 transgenic mice with infectious L. donovani to check the potency of an individual peptide or cocktail to protect mice against the infectious Leishmania parasite.
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